LavacaUSA

Lavaca is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for patients with inflammatory and fibrotic diseases. The company's lead candidate, LVC-001, is a potent and selective small molecule antagonist of GPR84, a receptor highly expressed on immune cells and involved in the progression of fibrosis. Lavaca is currently advancing LVC-001 through clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH). By targeting the underlying inflammatory and fibrotic pathways, the company aims to provide transformative treatment options for chronic diseases with high unmet medical needs.